Lilly quietly completes purchase of Padcev competitor, estimated at nearly half a billion dollars
Synaffix has landed another antibody-drug conjugate (ADC) partner. After inking deals with Genmab and MacroGenics this year alone, the Dutch biotech has landed a partnership with Emergence Therapeutics that could be worth $360 million.
Emergence Therapeutics strengthens leadership team with the appointment of Hatem Azim as Chief Medical Officer Duisburg, Germany, 7 June 2022. Emergence Therapeutics AG, a biopharmaceutical company...
Duisburg, Germany, 7 December 2021. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces that it has closed an €87 million series A financing round.
Duisburg, Germany, 7 December 2021. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces that it has closed an €87 million series A financing round.
Emergence Therapeutics AG, a Biopharmaceutical company developing novel antibody drug conjugates ( ADC ) for the treatment of cancers with high unmet needs, has closed an €87 million ($97.9 million) series A financing round.